Biotech success should not be measured in whether every Canadian company remains Canadian-owned

We should create and fund early-stage startups while allowing acquisitions—foreign or otherwise—to recycle capital, experienced executives, and technical expertise back into the ecosystem.

Health Minister Marjorie Michel, left, and Industry Minister Mélanie Joly. One of Canada’s biggest weaknesses in the life sciences is the separation between health care and innovation, write Pieter Cullis and Terri Petkau.The Hill Times photographs by Andrew Meade and Sam Garcia

Opinion

BY PIETER CULLIS, TERRI PETKAU

September 16, 2026

The federal Pharmaceutical and Life Sciences Sector Task Force recently delivered 39 recommendations to the min...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Tuesdays: Innovation & Industry Newsletter

The policies, decisions, and people working on investment and regulation in the industry and innovation realm.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy

FOLLOW THE HILL TIMES: